Sustained Acoustic Medicine (SAM) for Symptomatic Treatment of Pain Related to Bone Fracture

Description

The purpose of this study is to assess the ability of long-duration low-intensity therapeutic ultrasound (LITUS) to alleviate bone-fracture related pain over a 12-week period. The primary objective of this study is to evaluate the analgesic effect of LITUS in subjects suffering from bone-fracture pain. Secondary objectives are to assess the ability of LITUS to improve patients return to work time.

Conditions

Bone Fracture, Fresh Fracture

Talk to us

Study Overview

On this page

Study Details

Study overview

The purpose of this study is to assess the ability of long-duration low-intensity therapeutic ultrasound (LITUS) to alleviate bone-fracture related pain over a 12-week period. The primary objective of this study is to evaluate the analgesic effect of LITUS in subjects suffering from bone-fracture pain. Secondary objectives are to assess the ability of LITUS to improve patients return to work time.

Sustained Acoustic Medicine (SAM) for Symptomatic Treatment of Pain Related to Bone Fracture

Sustained Acoustic Medicine (SAM) for Symptomatic Treatment of Pain Related to Bone Fracture

Condition
Bone Fracture
Intervention / Treatment

-

Contacts and Locations

Trumbull

ZetrOZ Systems LLC, Trumbull, Connecticut, United States, 06611

Lansdowne Town Center

National Sports Medicine Institute, Lansdowne Town Center, Virginia, United States, 20176

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Have physician-diagnosed bone fracture
  • * Are between 18-80 years of age
  • * Report a pain score between 3-7 (range: 0-10) prior to enrolment
  • * Report that pain from fracture negatively affects quality of life
  • * Are willing not to use any cream, gel, or topical solution during the administration of treatment other than the approved treatment provided to the subject at the initiation of the study
  • * Are deemed appropriate by their physician or by the study site physician to participate.
  • * Be willing and able to self-administer treatment daily within their place of residence or during normal daily activity, excluding bathing, showering, or other water activities which may result in submersion of the study device.
  • * Not use or initiate opioid and/or non-opioid analgesic medications.
  • * Be willing to discontinue any other interventional treatment modalities on the affected area during the study period (e.g., transcutaneous electrical nerve stimulation, electronic muscle stimulation, traditional ultrasound).
  • * Cannot successfully demonstrate the ability to put on and take off the device.
  • * Displays any condition which, in the judgment of the investigator, would make participation in the study unacceptable including, but not limited to, the subject's ability to understand and follow instructions.
  • * Participated in a clinical trial for an investigational drug and/or agent within 30 days prior to screening.
  • * Is pregnant.
  • * Is a prisoner.
  • * Is non-ambulatory (unable to walk).
  • * Has a pacemaker.
  • * Has a malignancy in the treatment area.
  • * Has an active infection, open sores, or wounds in the treatment area.
  • * Has impaired sensation in the treatment area, such as caused by chemotherapy or anesthesia.
  • * Has a known neuropathy (disease of the brain or spinal nerves).
  • * Has a hereditary disposition (tendency) for excessive bleeding (hemorrhage).
  • * Are currently taking steroids.

Ages Eligible for Study

18 Years to 80 Years

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

Yes

Collaborators and Investigators

ZetrOZ, Inc.,

George K. Lewis, Ph.D., PRINCIPAL_INVESTIGATOR, ZetrOZ Systems

Study Record Dates

2024-12-31